Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Similarity of QL1203 and Vectibix in RAS Wild-Type Metastatic Colorectal Cancer
NCT07829588Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2026
- Primary completion
- Feb 2028
01
Overview
Phase 1, randomised, double-blind trial of ql1203 in colorectal cancer (CRC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Area under the concentration-time curve during a dosing interval at single dose and Area under the concentration-time curve during a dosing interval at steady state. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ql1203
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07829588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829588.